Demant A/ S stock (DK0010268440): Q1 2026 revenue beats forecasts with 16% growth

Demant A/S released its Q1 2026 earnings on May 13, 2026, reporting total revenue growth of 16%, comprising 6% organic growth and 10% from acquisitions, according to the earnings call transcript as of May 13, 2026. The stock rose 9% following the announcement, reflecting investor approval of the beat on forecasts.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

Demant A/S: core business model

Demant A/S develops, manufactures and sells hearing aids, hearing care systems and related services worldwide. The company operates through two main segments: Hearing Care and Professional Audio. Hearing Care, which generates the bulk of revenue, includes Oticon and Bernafon branded hearing devices distributed via clinics and retail. Demant employs over 20,000 people and serves millions of customers annually.

The Professional Audio division provides audio solutions for live sound, installations and consumer wireless products under brands like Oticon and Kind.

Main revenue and product drivers for Demant A/S

Hearing Care drove Q1 2026 growth with strong demand for premium hearing aids incorporating AI and connectivity features. Organic growth of 6% reflects resilient consumer spending on health tech in mature markets like the US and Europe, per the Q1 report published May 13, 2026.

Acquisitions contributed 10% to top-line expansion, bolstering Demant's position in audiology diagnostics and telehealth services relevant to US healthcare providers.

Industry trends and competitive position

The global hearing aid market is projected to grow at 6-8% CAGR through 2030, driven by aging populations and OTC hearing aid regulations in the US. Demant holds a top-three market share globally, competing with Sonova, WS Audiology and GN Store Nord.

Demant's innovation in rechargeable, Bluetooth-enabled devices aligns with US trends toward consumer-friendly audiology post-FDA OTC approval in 2022.

Why Demant A/S matters for US investors

Demant generates significant revenue from North America, with exposure to the $7 billion US hearing aid market. Its products are sold through US clinics and online, benefiting from Medicare expansions and private insurance coverage growth. Nasdaq Copenhagen listing offers US investors ADR access or direct trading via brokers.

Conclusion

Demant A/S delivered a solid Q1 2026 with revenue beating forecasts amid organic and acquisitive growth. The hearing care leader continues investing in tech-driven products amid favorable demographics. Investors track upcoming quarters for sustained momentum in key markets including the US.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.